Treatment of multidrug-resistant Pseudomonas aeruginosa infections: more attention required to in vitro studies[J]. Clinical Microbiology and Infection, 2005, 11(10): 856-857Zavascki AP.Treatment of multidrug-resistant Pseudomonas aeruginosa infections:more attention required to in vitro studies[J]....
Infections arising from multidrug-resistant pathogenic bacteria are spreading rapidly throughout the world and threaten to become untreatable. The origins of resistance are numerous and complex, but one underlying factor is the capacity of bacteria to ra
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:resistance mechanisms and implications for therapy [J]. 2010,8 .Zavascki AP, Carvalhaes CG, Picao RC, et al. Multidrug-resist- ant Pseudomonas aeruginosa and Acinetobacter baumannii re- sistance mechanisms and implications for therapy[...
Heimesaat, Markus M.Repvon Klitzing E, Ekmekciu I, Kuhl AA, Bereswill S, Heimesaat MM. Multidrug-resistant Pseudomonas aeruginosa aggravates inflammatory responses in murine chronic colitis. Sci Rep. (2018) 8:6685. doi: 10.1038/s41598-018-25034-2...
Background: Multidrug-Resistant organisms (MDRO) pose a global health threat due to overuse of antibiotics and genetic transfer of resistance. The Middle East, including Saudi Arabia, faces unique challenges in combating MDROs, necessitating tailored interventions. Objectives: This research...
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Author(s): Alexandre P Zavascki [[dagger]] 1 , Cec铆lia G Carvalhaes 2 , Renata C Pico 3 , Ana C Gales 4 Keywords : [beta]-lactamases; carbapenems; efflux ... AP ...
Pseudomonas aeruginosa 1 (0.8%) 0 1 (0.6%) Tigecycline-resistant 2 (1.7%) 1 (1.7%) 3 (1.7%) Relatives in healthcare settings (+) (P = 0.06)c E. coli 1 (0.8%) 0 1 (0.6%) Enterobacter hormaechei 1 (0.8%) 0 1 (0.6%) K. pneumoniae 0 1 (1.7%) 1 (0.6%) –, ...
(range 27–82 days), including treatment in neurological rehabilitation centers. Overall, our results show that neither colonization or infection with multidrug-resistant agents nor the subsequent isolation leads to a worse outcome. This result is surprising. Our trial involved several factors that ...
J. et al. A monoclonal antibody–Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl Acad. Sci. USA 84, 4288–4292 (1987). Article CAS PubMed PubMed Central Google Scholar Heike, Y. et al. Monoclonal anti-P-glycoprotein antibody-dependent killing of ...
Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Nosocomial infections due to multidrug-resistant pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25:1353-1364.Maragakis LL (... LL Maragakis - 《Critical Care Medicine》...